Introduction
Outcome from head injury is variable and cannot be predicted purely on the basis of clinical features or radiological findings 1, 2 . It has been observed that apparently similar patients will have different outcomes despite similar injuries and clinical treatment. Thornhill et al. 3 demonstrated that age of over 40 years, pre-existing physical disability and a history of brain illness were independent predictors of poor outcome after mild brain injury. However 35% of patients without any of these factors still failed to achieve a good outcome. This suggests that other features, such as genetic variability, may determine an individual's response to head injury 4 .
Clinical outcome after traumatic brain injury (TBI) is in part determined by secondary processes, occurring after the initial injury. A systemic and neuroinflammatory response is provoked after TBI and the magnitude and duration of this response may influence clinical outcome 5 in the short term potentially by promoting neuronal death, oedema and pyrexia and in the long term by influencing repair processes. The response is primarily mediated by cytokines 6 and the production of these cytokines may be altered by variation of the DNA sequence within their genes (gene polymorphisms). Understanding the role of cytokine gene polymorphisms in determining outcome after head injury may have important implications in understanding the neuroinflammatory response after brain injury, for prognosis after injury and possibly future treatment of patients who sustain head injury. To date there is little information attempting to correlate cytokine gene polymorphisms with outcome after TBI and studies that have been performed have been of small cohorts 7, 8, 9, 10 .
In this study we screened a panel of cytokine gene polymorphisms in a much larger patient cohort than has previously been published. A single nucleotide polymorphism Tumour Necrosis Factor-α (TNF-α, protein; TNFA, gene) is a classical proinflammatory cytokine which plays an important role in initiating and controlling the inflammatory response. In the central nervous system (CNS) TNF-α is produced primarily by microglia and astrocytes. TNF-α is known to be upregulated in the CNS after TBI 11, 12, 13 and in clinical studies raised levels of TNF-α in plasma and cerebrospinal fluid have been demonstrated in patients after TBI 14, 15 . Experimental studies have shown evidence that TNF-α may both exacerbate neuronal injury and be neuroprotective. For example, studies of TNF knock out mice have shown that deficiency of TNF-α is beneficial early after trauma but causes deleterious effects in the long term 16 . In human studies variation in the TNF-α promoter region has been associated with susceptibility to cerebral malaria 17 dbSNP ID: 361525) SNPs within the promoter region of the TNFA gene have been most extensively explored and therefore were investigated in this study.
Interleukin-1 (IL1), acting together with TNF-α, has a major role in the production of inflammation and the generation of pyrexia. The IL1 family consists of two agonists of the IL1 receptor (IL1α and IL1β) and an antagonist (IL1ra). Microglia are the main source of IL1 in the CNS and there is rapid IL1 upregulation after acute CNS injury, including TBI 20 , with evidence that it exacerbates neuronal damage 21 . Four IL1
SNPs have been shown to influence transcription and/or have been associated with human CNS disease 22, 23, 24 and were therefore included in this study: IL1A -889 (C/T; dbSNP ID 1800587), IL1B -31 (C/T; dbSNP ID 1143627), IL1B -511 (G/T; dbSNP ID 16944) and IL1B +3953 (C/T; 1143634).
Interleukin-6 (IL6) plays an important role in the acute phase response. IL6
production, in the CNS primarily by microglia, is stimulated by TNF and IL1 and high levels have been associated with better outcome in human TBI 25, 26 . SNPs identified in the promoter region of IL6 influence transcription through complex interactions 27 and therefore the following SNPs were included in this study: IL6 -174 (G/C; 1800795), -572 (G/C; 1800796) and -597 (G/A; 1800797).
Transforming Growth Factor (TGF) -β has a role in the CNS in cell proliferation, differentiation and inflammation. Microglia and astrocytes are the main source of TGF after injury and it has a mainly anti-inflammatory action, limiting microglial activation and having neuroprotective effects. Two SNPs located in the promoter region are associated with higher concentrations of TGF in the plasma and therefore were included in this study: TGFB -509 (C/T; 1800469) and TGFB -800 (G/A; 1800468).
Using a previously identified large cohort of patients who had sustained TBI 28 we have addressed the hypothesis that cytokine gene polymorphisms, potentially by altering the magnitude and duration of the neuroinflammatory response, influence clinical outcome at six months post head injury.
Methods

Sample
The participants in this study were recruited from consecutive head injury admissions to the regional Neurosurgical Unit for the West of Scotland at the Institute of Neurological Sciences, Glasgow from 1996 to 1999. Appropriate consent was obtained and the patients were originally entered into a study of the relationship between APOE genotype and outcome after head injury and details of this cohort are as outlined previously 28 . Consent for inclusion in the study had been obtained from the patient's next of kin or carer and a buccal swab sample was taken for genotyping.
In patients who died rapidly or if no responsible person was available a buccal swab was not performed but the residue of a blood sample which had been taken for routine clinical analysis was stored and analysed subsequently after consent had been obtained. Survivors were invited to approve use of clinical outcome data at late follow up. The ethical committee gave permission for anonymised genotyping for the small number of patients who were not able to give consent and who had no responsible relative. 
Genotyping
Genotyping was performed on buccal swabs or blood samples. Collection and preparation of the buccal swabs was performed as detailed previously 33 . In order to perform multiple SNP assays on the limited amount of DNA available a preamplification step was utilised using the GenomiPhi kit (GE Healthcare). This utilises the bacteriophage Phi29 polymerase to exponentially amplify linear DNA template by strand displacement Based upon results from this screen (described below), genotyping for the TNFA -308 SNP (rs1800629) was performed using a PCR protocol similar to that used previously for APOE genotyping of this cohort 28 , except that primers for PCR were used which span the -308 region of the TNFA promoter (forward: 5'-aggcaataggttttgaggggcat-3' and reverse: 5'-tcctccctgctccgattccg-3'). The PCR products were then digested with the restriction enzyme Nco 1 giving fragment sizes of 87bp and 20bp 35 . The digestion products were separated according to size by polyacrylamide gel electrophoresis, stained with ethidium bromide and viewed and photographed by u.v. transillumination.
Clinical outcome at 6 months was determined using the Glasgow Outcome Scale (GOS 
Results
Association between cytokine gene SNPs and outcome at 6 months
The combination of the multi-SNP assay methodology and the available DNA genotype and outcome at 6 months was assessed for each of the 11 cytokine SNPs.
In the initial screen, no SNPs reached statistical significance at the 0.05 level, 
Association between cytokine gene SNPs and secondary complications
Associations ( 
Association between the TNFA -308 SNP and Glasgow Outcome Scale at six months
After repeating and extending TNFA -308 SNP typing with the Nco1 restriction digest method there were 965 patients in the initial cohort identified who had an acute head injury, were included in the original APOE study, consented, and had both APOE genotype and TNF -308 SNPtype available.
Twenty eight patients for whom GCS motor response was recorded as untestable either on admission to first hospital or on admission to study hospital (n = 1), pupil reactivity was not available either on admission to first hospital or on admission to study hospital (n = 21), or CT scan was not done (n = 6) were excluded. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
The remaining 937 patients had missing values for traumatic subarachnoid haemorrhage on admission CT scan (n = 7), hypoxia in first 24 hours (n = 73), hypotension in first 24 hours (n = 72) and values for these were imputed.
TNFA genotype was 1.1 for 595 (63.5%), 1.2 for 298 (31.8%), and 2.2 for 44 (4.7%) of the 937 patients ( Table 1) .
The characteristics of patients who were TNFA -308 allele 2 carriers were similar to non-carriers with respect to age, gender, initial GCS (reflecting the severity of injury),
CT characteristics of the injuries, presence of hypoxia and hypotension and APOE ε4 allele carriage (table 2) .
In our previous studies investigating APOE genotype, outcome was dichotomised into unfavourable (death, vegetative survival or severe disability at 6 months) and favourable (moderate disability or good recovery) 28, 36 . Analysed in this manner, TNFA -308 allele 2 carriers were more likely to have an unfavourable outcome than non-carriers (39% vs. 31%) (table 3).
The proportion of head injured patients who died was similar for allele 2 carriers and non-carriers (13% vs. 12%). However allele 2 carriers who survived were more likely to have severe disability (25% vs. 18%) and less likely to have a good outcome (37% vs. 43%).
The association between possession of the TNFA -308 allele 2 and poor outcome 6 months after head injury ( 
Association between TNFA -308 SNP and secondary complications
Possession of the TNFA -308 allele 2 does not appear to influence the complications of pyrexia during the first 24 hours of admission, raised intracranial pressure during admission or seizure occurrence during admission after TBI. There is a nonsignificant trend towards a lower likelihood of life-threatening infection in allele 2 carriers during admission after TBI (Table 5) .
Discussion
This study is the first to show a significant association between the TNFA -308 polymorphism and overall 6 month outcome after TBI. Thus, TNFA -308 allele 2 carriers were more likely to have an unfavourable outcome compared with noncarriers. There were also relatively weak associations between SNPs in other cytokine genes and some of the secondary complications of head injury: IL1A -889 and seizures; both IL1A -889 and IL1B +3953 and raised intracranial pressure; and IL1B -31 and severe sepsis.
The strengths of a study of this nature in this cohort have previously been outlined 28 .
These include the large number of subjects in the cohort, prospective recruitment from consecutive admissions to a regional centre and follow-up achieved in a very high proportion of initial participants.
The association between TNFA -308 allele 2 and poor outcome may reflect that
TNFα plays a pivotal role in the initiation and control of the inflammatory response after TBI 37, 38 . TNFα has been shown to be upregulated in the CNS after TBI 11, 12, 13, 39 and raised levels of TNFα have been demonstrated in plasma and cerebrospinal fluid after TBI 14, 15 . The TNFA -308 polymorphism sits within the promoter region of the gene and alters transcription, allele 2 being associated with significantly higher This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
expression of TNFα 40, 41 . Association between the TNFA -308 polymorphism and outcome after TBI is therefore biologically plausible as the genetic variation is in a position to influence expression of TNFα in response to a stimulus such as TBI.
Experimental studies show that TNFα has a role in mediating neuronal death in the acute phase and in promoting neuronal repair and plasticity in the longer term 42, 43 , with differential effects according to activation of specific TNFα receptor subtypes 44, 45 , so TNFα could influence outcome in both the short and longer term after human TBI in potentially complex ways. A number of groups have investigated the relationship between cytokine protein measurements, including TNFα, in the CSF with outcome after TBI in relatively small cohorts without demonstrating evidence of a correlation between high TNFα levels and poor outcome 46, 47 . However, it has been
shown that serum and CSF TNFα, correlate with the occurrence of the secondary complications of intracranial hypertension and decreased cerebral perfusion pressure 48, 49 . Alterations in other cytokines have also been studied after TBI with increases in IL-1β and IL-6 correlating with poor outcome 50 or without a clear relationship to outcome 51 .
The relationship between levels of TNFα in the CSF, which is obviously relatively accessible for sampling, and the timecourse and localisation of its production and utilisation in the brain in response to the multiple primary and secondary forms of pathology that occur after TBI is currently unclear and may not be a simple relationship. In post mortem human brain tissue both TNF mRNA and protein are detectable within a few minutes of TBI 52 whereas the rise in TNF in the CSF is delayed and sustained over a matter of days to weeks 38 . Despite these complexities, the results of this study generate the simple hypothesis that carriers of TNFA -308 allele 2 have increased expression of TNFα in response to TBI which in turn is responsible for their worse outcome. Further studies of patients with TBI genotyped for the TNFA -308 polymorphism, involving measurement of serum, CSF, . The gene sits within the MHC cluster on chromosome 6, and is closely related to the lymphotoxin- and - genes. The probability is that TNFA SNPs form part of a haplotype that stretches across these closely related genes, and therefore it is difficult to ascribe an apparent association to a single causative SNP within this region This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
